Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 10/20 | 0.55 |
| ▸ | HRH1 | P35367 | 6/20 | 0.55 |
| ▸ | HTR2B | P41595 | 6/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261830 | 0.94 | MCHR1 (0.66) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4261823 | 0.94 | MCHR1 (0.66) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| Trifluoroacetic Acid SCHEMBL4261967 | 0.81 | MCHR1 (0.62) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4256547 | 0.78 | IRAK4 (0.41) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| Trifluoroacetic Acid SCHEMBL6831616 | 0.78 | MCHR1 (0.69) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| Trifluoroacetic Acid SCHEMBL6456478 | 0.78 | MCHR1 (0.69) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| Trifluoroacetic Acid SCHEMBL3943121 | 0.77 | MCHR1 (0.91) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| Trifluoroacetic Acid SCHEMBL3943117 | 0.77 | MCHR1 (0.91) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL4258534 | 0.75 | MCHR1 (0.71) | MCHR1ADRA2AHRH1HTR2BADRA1A | |
| SCHEMBL6467575 | 0.75 | MCHR1 (1.00) | MCHR1ADRA2AHRH1HTR2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | MCHR1 3/4885ADRA2A 178/4885HRH1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.